We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
+24.79%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$1.9B
AUM Growth
+$119M
Cap. Flow
+$19.1M
Cap. Flow %
1.01%
Top 10 Hldgs %
50.01%
Holding
78
New
5
Increased
8
Reduced
9
Closed
7

Top Buys

Rank Stock Value
1
AXSM icon
Axsome Therapeutics
AXSM
+$23.9M
2
GERN icon
Geron
GERN
+$18.1M
3
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$17.6M
4
FATE icon
Fate Therapeutics
FATE
+$16.9M
5
APLS
Apellis Pharmaceuticals
APLS
+$14.4M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$22.1M
2
ACAD icon
Acadia Pharmaceuticals
ACAD
+$20.7M
3
BPMC
Blueprint Medicines
BPMC
+$18.1M
4
VERU icon
Veru
VERU
+$17.7M
5
KNTE
Kinnate Biopharma Inc. Common Stock
KNTE
+$8.25M

Sector Composition

Rank Sector Weight
1 Healthcare 99.67%
2 Financials 0.33%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RXDX
1
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$209M 11%
1,897,500
+183,500
+11% +$11.9M
ONC
2
BeOne Medicines Ltd
ONC
$32.8B
$110M 5.8%
500,000
– –
CYTK icon
3
Cytokinetics
CYTK
$10.5B
$96.2M 5.07%
2,100,000
– –
RVMD icon
4
Revolution Medicines
RVMD
$39.9B
$94.9M 5%
3,984,264
– –
MRTX
5
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$90.6M 4.78%
2,000,000
– –
SWTX
6
DELISTED
SpringWorks Therapeutics
SWTX
$89M 4.69%
3,421,541
– –
APLS
7
DELISTED
Apellis Pharmaceuticals
APLS
$81.5M 4.3%
1,576,000
+272,300
+21% +$14.4M
AMLX icon
8
Amylyx Pharmaceuticals
AMLX
$2.26B
$77M 4.06%
2,084,000
– –
TNGX icon
9
Tango Therapeutics
TNGX
$4.43B
$51.6M 2.72%
7,123,642
+252,000
+4% +$1.77M
TYRA icon
10
Tyra Biosciences
TYRA
$1.9B
$49M 2.58%
6,448,359
– –
RETA
11
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$46.7M 2.46%
1,230,004
-8,996
-0.7% -$310K
AKRO
12
DELISTED
Akero Therapeutics
AKRO
$45.6M 2.4%
831,495
– –
ITOS
13
DELISTED
iTeos Therapeutics
ITOS
$42.1M 2.22%
2,154,058
– –
SAGE
14
DELISTED
Sage Therapeutics
SAGE
$41.7M 2.2%
1,094,000
– –
ANAB icon
15
AnaptysBio
ANAB
$1.58B
$40.3M 2.12%
1,300,000
– –
IDYA icon
16
IDEAYA Biosciences
IDYA
$3.42B
$40M 2.11%
2,202,812
– –
CNTA
17
DELISTED
Centessa Pharmaceuticals
CNTA
$38.8M 2.04%
1,251,137
– –
NUVL
18
DELISTED
Nuvalent
NUVL
$36M 1.9%
1,210,192
– –
RLAY icon
19
Relay Therapeutics
RLAY
$4.1B
$32.4M 1.71%
2,169,132
– –
AXSM icon
20
Axsome Therapeutics
AXSM
$11.2B
$30.9M 1.63%
+400,000
New +$23.9M
RCUS icon
21
Arcus Biosciences
RCUS
$3.55B
$29.6M 1.56%
1,432,200
– –
MRUS
22
DELISTED
Merus
MRUS
$29.4M 1.55%
1,900,000
– –
RCKT icon
23
Rocket Pharmaceuticals
RCKT
$340M
$28.7M 1.51%
1,466,051
– –
FOLD
24
DELISTED
Amicus Therapeutics
FOLD
$28.4M 1.5%
2,325,000
– –
VTYX
25
DELISTED
Ventyx Biosciences
VTYX
$27.9M 1.47%
850,000
– –
1
2 3 4

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q4 2022 Portfolio in Review

As of Q4 2022, Boxer Capital held 78 positions worth $1.9B, up 6.7% from $1.78B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Boxer Capital's Q4 2022 filing shows 5 new, 8 increased, 9 reduced and 7 closed positions. Its largest new stake was Axsome Therapeutics: 400,000 shares worth $30.9M. The largest sale was Sarepta Therapeutics, an estimated $22.1M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Financials.

  • Boxer Capital's largest Q4 2022 buy was Axsome Therapeutics: 400,000 shares worth $30.9M.
  • Boxer Capital added most to Fate Therapeutics in Q4 2022, an estimated $16.9M increase.
  • Boxer Capital's biggest Q4 2022 reduction was Veru, cutting an estimated $17.7M.
  • Boxer Capital fully exited Sarepta Therapeutics in Q4 2022, selling an estimated $22.1M.
  • Boxer Capital's ten largest holdings make up 50% of its $1.9B portfolio in Q4 2022.
  • Boxer Capital opened 5 new positions and closed 7 in Q4 2022.
  • Boxer Capital's portfolio value rose 6.7% quarter-over-quarter to $1.9B.

Based on Boxer Capital's 13F filing for Q4 2022, filed 14 Feb 2023.